Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class (i) targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended September 30,
Vivos Therapeutics Inc. shares jumped more than 270% Wednesday after the medical-device maker got regulatory clearance for removable oral appliances that treat obstructive sleep apnea. The U.S ...
New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and ChildrenLITTLETON, Colo., Oct. 08, 2024 (GLOBE NEWSWIRE ...
An unhealthy diet and an indolent life are well known causes of heart disease and stroke. But sleep apnea—where people ...
Effective January 1, 2025, these codes will streamline insurance coverage and reimbursement for Vivos’ devices, designed to treat obstructive sleep apnea (OSA) in both adults and children.
New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and Children LITTLETON, Colo., Oct. 08, 2024 (GLOBE NEWSWIRE) -- ...
A common yet underdiagnosed sleep disorder contributes to the development of dementia among adults -; particularly women, a ...
Obstructive sleep apnea – disruptive snoring – is linked to conditions such as high blood pressure and heart disease and other hazards to your health. Learn more from WebMD. Pillows that put ...
Sleep apnea is a condition where your breathing stops and starts while you're sleeping, and it affects over 936 million people worldwide. Because sleep apnea is so common, it's likely that you ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback